Literature DB >> 27478200

Treatment of relapsed and refractory multiple myeloma.

Pieter Sonneveld1, Annemiek Broijl2.   

Abstract

Entities:  

Keywords:  chemotherapy; immunotherapy; multiple myeloma; relapse

Year:  2016        PMID： 27478200      PMCID： PMC4967579          DOI： 10.3324/haematol.2016.148882

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.

Authors:  R Chakraborty; E Muchtar; S K Kumar; F K Buadi; D Dingli; A Dispenzieri; S R Hayman; W J Hogan; P Kapoor; M Q Lacy; N Leung; M A Gertz
Journal:  Bone Marrow Transplant       Date:  2017-11-13       Impact factor: 5.483

2.  Possibilities and limitations of an in vitro three-dimensional bone marrow model for the prediction of clinical responses in patients with relapsed multiple myeloma.

Authors:  Maaike V J Braham; Jacqueline Alblas; Wouter J A Dhert; F Cumhur Öner; Monique C Minnema
Journal:  Haematologica       Date:  2019-04-19       Impact factor: 9.941

3.  Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.

Authors:  S Ailawadhi; J R Mikhael; B R LaPlant; K M Laumann; S Kumar; V Roy; D Dingli; P L Bergsagel; F K Buadi; S V Rajkumar; R Fonseca; M A Gertz; P Kapoor; T Sher; S R Hayman; A K Stewart; A Dispenzieri; R A Kyle; W I Gonsalves; C B Reeder; Y Lin; R S Go; N Leung; T Kourelis; J A Lust; S J Russell; A A Chanan-Khan; M Q Lacy
Journal:  Leukemia       Date:  2017-09-01       Impact factor: 11.528

4.  Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT.

Authors:  Jiang-Hua Ding; Li-Ya Yuan; Guo-An Chen
Journal:  Oncol Lett       Date:  2016-12-08       Impact factor: 2.967

5.  Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

Authors:  Paul G Richardson; William I Bensinger; Carol Ann Huff; Caitlin L Costello; Nikoletta Lendvai; Jesus G Berdeja; Larry D Anderson; David S Siegel; Daniel Lebovic; Sundar Jagannath; Jacob P Laubach; Keith E Stockerl-Goldstein; Long Kwei; Fong Clow; Laurence Elias; Zeena Salman; Thorsten Graef; Elizabeth Bilotti; Ravi Vij
Journal:  Br J Haematol       Date:  2018-02-13       Impact factor: 6.998

6.  Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.

Authors:  David Baker; Milan Bimali; Luis Carrillo; Archana Sachedina; Daisy Alapat; Md Shadiqul Hoque; Mathew Kottarathara; Richa Parikh; Amani Erra; Angel A Mitma; Pankaj Mathur; Yetunde Ogunsesan; Lakshmi Yarlagadda; Sravani Gundarlapalli; Sharmilan Thanendrarajan; Maurizio Zangari; Frits Van Rhee; Guido Tricot; Carolina Schinke
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941

7.  Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort.

Authors:  Nadjoua Maouche; Bhuvan Kishore; Zara Bhatti; Supratik Basu; Farheen Karim; Sharadha Sundararaman; Freya Collings; Bing Tseu; Heather Leary; Noel Ryman; Udaya Reddy; Grant D Vallance; Jaimal Kothari; Karthik Ramasamy
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752

8.  Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.

Authors:  Roman Hájek; Michel Delforge; Marc S Raab; Paul Schoen; Lucy DeCosta; Ivan Spicka; Jakub Radocha; Ludek Pour; Sebastian Gonzalez-McQuire; Walter Bouwmeester
Journal:  Br J Haematol       Date:  2019-08-06       Impact factor: 6.998
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.